- 2025,09,15
Chengli Pharmaceutical (603811.SH) announced that its wholly-owned subsidiary Fujian Huakang Pharmaceutical Co., Ltd. recently obtained the result of the drug GMP compliance inspection (No. FJSC2026-038) from the official website of Fujian Medical Products Administration.
The inspection result shows that the newly added production line for glucosamine hydrochloride API in Workshop B09 of Fujian Huakang fully complies with the requirements of Good Manufacturing Practice for Drugs (Revised 2010) and its appendices in terms of production and quality management.
The successful passing of this GMP compliance inspection indicates that the relevant production line of Fujian Huakang has met compliant production conditions, and its product quality control and production management system have reached national standards.
This will help the company further guarantee the stability of product quality, maintain consistent and stable production capacity, so as to better meet the growing market demand for glucosamine hydrochloride API.
Overall, this positive achievement will positively drive the long-term development of Chengli Pharmaceutical, consolidate its competitive advantages in the industry and lay a solid foundation for future business expansion.
